Tecan reports financial results for the first half of 2024 and revises its outlook for full year 2024

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports financial results for the first half of 2024 and revises its outlook for full year 2024 Financial results for the first half of 2024 – Highlights Sales of CHF 467.2 million (H1 2023: CHF 541.5 million) Sales development of -11.6% in local currencies or -13.7% in Swiss francsDecline in sales mainly due to softness in the instrument business with biopharmaceutical companies globally and general ma